Losmapimod (FHD-286)

About Fulcrum Therapeutics

Fulcrum Therapeutics is pioneering a novel approach to drug discovery by targeting the mechanisms that control gene expression to treat genetically defined diseases. The company's lead program, losmapimod, is in Phase 3 development for facioscapulohumeral muscular dystrophy (FSHD), a debilitating muscle disorder with no approved therapies. Fulcrum's platform leverages functional genomics to identify master regulator proteins that can be targeted with small molecules, aiming to correct imbalanced gene expression and address the underlying cause of disease. The company's strategy focuses on high-unmet-need rare diseases where its technology can deliver transformative treatments.

Therapeutic Areas

Other Facioscapulohumeral Muscular Dystrophy (FSHD) Drugs